• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ICON plc downgraded by Goldman with a new price target

    3/21/25 8:04:11 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ICLR alert in real time by email
    Goldman downgraded ICON plc from Buy to Neutral and set a new price target of $200.00 from $250.00 previously
    Get the next $ICLR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ICLR

    DatePrice TargetRatingAnalyst
    7/24/2025$224.00Neutral → Outperform
    Robert W. Baird
    4/29/2025$150.00Overweight → Neutral
    Analyst
    4/14/2025$157.00Buy → Hold
    TD Cowen
    4/10/2025$165.00Overweight → Equal Weight
    Barclays
    3/21/2025$250.00 → $200.00Buy → Neutral
    Goldman
    1/7/2025$263.00Outperform
    RBC Capital Mkts
    10/24/2024$340.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Neutral
    Redburn Atlantic
    More analyst ratings

    $ICLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ICON plc upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded ICON plc from Neutral to Outperform and set a new price target of $224.00

      7/24/25 7:19:33 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by Analyst with a new price target

      Analyst downgraded ICON plc from Overweight to Neutral and set a new price target of $150.00

      4/29/25 8:06:12 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by TD Cowen with a new price target

      TD Cowen downgraded ICON plc from Buy to Hold and set a new price target of $157.00

      4/14/25 8:13:29 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ICON Announces Results of Annual General Meeting

      ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: RESOLUTION NUMBER RESOLUTION     TOTAL NUMBER OF VOTES     VOTE FOR     VOTE AGAINST     VOTE WITHHELD                   1.1

      7/23/25 4:20:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON Reports Second Quarter 2025 Results

      Highlights Gross business wins in the quarter of $2,966 million, representing an increase of 10.6% on quarter one 2025. Net business wins in the quarter of $2,057 million; a net book to bill in the quarter of 1.02. Quarter two revenue was $2,017.4 million representing an increase of 0.8% on quarter one 2025. Net income for the quarter was $183.0 million or $2.30 per diluted share, an increase of 30.7% on quarter two 2024 diluted earnings per ordinary share. Quarter two adjusted EBITDA was $396.0 million or 19.6% of revenue, representing an increase of 1.4% on quarter one 2025. Quarter two adjusted net income was $259.5 million or $3.26 per diluted ordinary share. Net de

      7/23/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report

      ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR). ICON outpaced the average phase 1 performance scores of other large CROs, solidifying its position as a premier partner for early phase clinical studies. The report, based on extensive feedback from 159 industry professionals, underscored ICON's dominance across a wide range of performance metrics and highlights the company's unwavering commitment to innovation, ope

      7/16/25 7:15:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    SEC Filings

    See more
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      7/24/25 4:44:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      7/23/25 4:36:53 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 6-K filed by ICON plc

      6-K - ICON PLC (0001060955) (Filer)

      7/23/25 4:32:42 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Leadership Updates

    Live Leadership Updates

    See more
    • ICON Announces Results of Annual General Meeting

      ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: RESOLUTION NUMBER RESOLUTION     TOTAL NUMBER OF VOTES     VOTE FOR     VOTE AGAINST     VOTE WITHHELD                   1.1

      7/23/25 4:20:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Anne Whitaker Appointed as Non-Executive Director

      MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

      4/3/25 6:13:56 PM ET
      $ICLR
      $TLX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • ICON Announces Appointment of Chief Operating Officer

      ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to

      12/18/24 7:00:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Financials

    Live finance-specific insights

    See more
    • ICON Reports Second Quarter 2025 Results

      Highlights Gross business wins in the quarter of $2,966 million, representing an increase of 10.6% on quarter one 2025. Net business wins in the quarter of $2,057 million; a net book to bill in the quarter of 1.02. Quarter two revenue was $2,017.4 million representing an increase of 0.8% on quarter one 2025. Net income for the quarter was $183.0 million or $2.30 per diluted share, an increase of 30.7% on quarter two 2024 diluted earnings per ordinary share. Quarter two adjusted EBITDA was $396.0 million or 19.6% of revenue, representing an increase of 1.4% on quarter one 2025. Quarter two adjusted net income was $259.5 million or $3.26 per diluted ordinary share. Net de

      7/23/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc Schedules Second Quarter 2025 Earnings Conference Call

      ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the second quarter 2025 after the market closes on Wednesday, July 23, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 24, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical researc

      6/23/25 6:30:00 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON Reports First Quarter 2025 Results

      Highlights Net business wins in the quarter of $2,022 million; a net book to bill in the quarter of 1.01. Closing backlog of $24.7 billion, an increase of 0.3% on quarter four 2024 and 6.0% on quarter one 2024. Quarter one revenue was $2,001.3 million and quarter one adjusted EBITDA was $390.7 million or 19.5% of revenue. GAAP net income for the quarter was $154.2 million or $1.90 per diluted share. Quarter one adjusted net income was $258.3 million or $3.19 per diluted share. Net debt was $2.9 billion at March 31, 2025 with a net debt to adjusted EBITDA ratio of 1.7x. $250.0 million worth of stock repurchased in quarter one at an average price of $184. Updating full-year 20

      4/30/25 4:15:00 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ICLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ICON plc

      SC 13G/A - ICON PLC (0001060955) (Subject)

      11/12/24 11:54:03 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by ICON plc (Amendment)

      SC 13G/A - ICON PLC (0001060955) (Subject)

      2/9/24 11:49:03 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by ICON plc (Amendment)

      SC 13G/A - ICON PLC (0001060955) (Subject)

      1/30/24 12:11:57 PM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care